Summit Therapeutics (SMMT) announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer, CRC, with the initiation of the global Phase III HARMONi-GI3 trial. Summit is starting a Phase III clinical study, HARMONi-GI3, to evaluate ivonescimab plus chemotherapy compared to bevacizumab plus chemotherapy as first line therapy in patients with unresectable metastatic colorectal cancer. Clinical trial sites for HARMONi-GI3 are planned to begin activating in the United States prior to the end of the year. The multiregional study intends to enroll approximately 600 patients. The primary endpoint for this study is progression-free survival.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Positive Outlook for Summit Therapeutics Driven by Anticipated HARMONi-6 Trial Success
- Promising Outlook for Summit Therapeutics: Buy Rating Driven by Anticipated HARMONi-6 Trial Performance and Share Price Growth
- Citi adds ’30-day upside catalyst watch’ on Summit Therapeutics
- Summit Therapeutics initiated with an Underweight at Barclays